1150 related articles for article (PubMed ID: 32979309)
21. Car T Cells in Solid Tumors: Overcoming Obstacles.
Rojas-Quintero J; Díaz MP; Palmar J; Galan-Freyle NJ; Morillo V; Escalona D; González-Torres HJ; Torres W; Navarro-Quiroz E; Rivera-Porras D; Bermúdez V
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673757
[TBL] [Abstract][Full Text] [Related]
22. State of the Art in CAR-T Cell Therapy for Solid Tumors: Is There a Sweeter Future?
Amorós-Pérez B; Rivas-Pardo B; Gómez Del Moral M; Subiza JL; Martínez-Naves E
Cells; 2024 Apr; 13(9):. PubMed ID: 38727261
[TBL] [Abstract][Full Text] [Related]
23. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.
Martinez M; Moon EK
Front Immunol; 2019; 10():128. PubMed ID: 30804938
[TBL] [Abstract][Full Text] [Related]
24. Armed with IL-2 based fusion protein improves CAR-T cell fitness and efficacy against solid tumors.
Li S; Xia Y; Hou R; Wang X; Zhao X; Guan Z; Ma W; Xu Y; Zhang W; Liu D; Zheng J; Shi M
Biochim Biophys Acta Mol Basis Dis; 2024 Jun; 1870(5):167159. PubMed ID: 38583815
[TBL] [Abstract][Full Text] [Related]
25. Evaluating CAR-T Cell Therapy in a Hypoxic 3D Tumor Model.
Ando Y; Siegler EL; Ta HP; Cinay GE; Zhou H; Gorrell KA; Au H; Jarvis BM; Wang P; Shen K
Adv Healthc Mater; 2019 Mar; 8(5):e1900001. PubMed ID: 30734529
[TBL] [Abstract][Full Text] [Related]
26. Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward.
Li J; Li W; Huang K; Zhang Y; Kupfer G; Zhao Q
J Hematol Oncol; 2018 Feb; 11(1):22. PubMed ID: 29433552
[TBL] [Abstract][Full Text] [Related]
27. [T cell-based immunotherapies in solid tumors].
Baulu E; Dougé A; Chuvin N; Bay JO; Depil S
Bull Cancer; 2021 Oct; 108(10S):S96-S108. PubMed ID: 34920813
[TBL] [Abstract][Full Text] [Related]
28. [Mechanisms of resistance and escape to CAR-T cells].
Grinda T; Brouard J; Tran D; Rubio MT
Bull Cancer; 2021 Oct; 108(10S):S128-S140. PubMed ID: 34920795
[TBL] [Abstract][Full Text] [Related]
29. Advances in Chimeric Antigen Receptor T-Cell Therapies for Solid Tumors.
Baybutt TR; Flickinger JC; Caparosa EM; Snook AE
Clin Pharmacol Ther; 2019 Jan; 105(1):71-78. PubMed ID: 30406956
[TBL] [Abstract][Full Text] [Related]
30. Single-Domain Antibody-Based TCR-Like CAR-T: A Potential Cancer Therapy.
Zhu L; Yang X; Zhong D; Xie S; Shi W; Li Y; Hou X; HuaYao ; Zhou H; Zhao M; Ding Z; Zhao X; Mo F; Yin S; Liu A; Lu X
J Immunol Res; 2020; 2020():2454907. PubMed ID: 32964055
[TBL] [Abstract][Full Text] [Related]
31. Chimeric Antigen Receptor-Modified T Cells and T Cell-Engaging Bispecific Antibodies: Different Tools for the Same Job.
Schwerdtfeger M; Benmebarek MR; Endres S; Subklewe M; Desiderio V; Kobold S
Curr Hematol Malig Rep; 2021 Apr; 16(2):218-233. PubMed ID: 33939108
[TBL] [Abstract][Full Text] [Related]
32. Solid Tumors Challenges and New Insights of CAR T Cell Engineering.
Tahmasebi S; Elahi R; Esmaeilzadeh A
Stem Cell Rev Rep; 2019 Oct; 15(5):619-636. PubMed ID: 31161552
[TBL] [Abstract][Full Text] [Related]
33. Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives.
Qu J; Mei Q; Chen L; Zhou J
Cancer Immunol Immunother; 2021 Mar; 70(3):619-631. PubMed ID: 33025047
[TBL] [Abstract][Full Text] [Related]
34. Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies.
Zhang ZZ; Wang T; Wang XF; Zhang YQ; Song SX; Ma CQ
Pharmacol Res; 2022 Jan; 175():106036. PubMed ID: 34920118
[TBL] [Abstract][Full Text] [Related]
35. CAR T-Cell Therapy in Hematological Malignancies.
Haslauer T; Greil R; Zaborsky N; Geisberger R
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445701
[TBL] [Abstract][Full Text] [Related]
36. Chimeric Antigen Receptor T-Cell Therapy in Glioblastoma: Current and Future.
Li L; Zhu X; Qian Y; Yuan X; Ding Y; Hu D; He X; Wu Y
Front Immunol; 2020; 11():594271. PubMed ID: 33224149
[TBL] [Abstract][Full Text] [Related]
37. Prolonged Persistence of Chimeric Antigen Receptor (CAR) T Cell in Adoptive Cancer Immunotherapy: Challenges and Ways Forward.
Jafarzadeh L; Masoumi E; Fallah-Mehrjardi K; Mirzaei HR; Hadjati J
Front Immunol; 2020; 11():702. PubMed ID: 32391013
[TBL] [Abstract][Full Text] [Related]
38. CAR-T cell therapy in melanoma: A future success story?
Simon B; Uslu U
Exp Dermatol; 2018 Dec; 27(12):1315-1321. PubMed ID: 30288790
[TBL] [Abstract][Full Text] [Related]
39. Making CAR T Cells a Solid Option for Solid Tumors.
Schmidts A; Maus MV
Front Immunol; 2018; 9():2593. PubMed ID: 30467505
[TBL] [Abstract][Full Text] [Related]
40. Charting new paradigms for CAR-T cell therapy beyond current Achilles heels.
Li Y; Hu Z; Li Y; Wu X
Front Immunol; 2024; 15():1409021. PubMed ID: 38751430
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
